FDA Approves GSK’s Hibsago for Chronic Hepatitis B
PHILADELPHIA, PA — GSK plc (NYSE: GSK) secured U.S. Food and Drug Administration approval for Hibsago, a hepatitis B treatment that achieved functional cure in 19% of eligible clinical trial …
FDA Approves GSK’s Hibsago for Chronic Hepatitis B Read More